



Olympus Corporation

Company Presentation

April 2025 Ver. 4 (Updated: June 2025)

Disclaimer:

- Any content or information (“Content”) presented herein is illustrative in nature and does not guarantee or represent specific information, outcomes or results.
- Under no circumstances shall Olympus or its employees, consultants, agents or representatives be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the Content or any use thereof.
- Some of the products and/or technology shown herein are future technology concepts that are under development and are not presently available in all countries, including not being available in the United States. There is no time period established as to when or if these products and/or technologies will be available in such markets, including the United States. The safety and effectiveness of these products and technologies and/or the use of these products and technologies have not yet been established in the United States market.

A background image with a blue tint showing two people in a meeting. A woman in the foreground is pointing at a glass wall with colorful sticky notes. A man stands behind her, looking on. The image is used as a background for a table of contents.

01 As a Globally Leading MedTech Company

02 Our Business Field

03 Company Strategy

04 For a Sustainable Society

05 Fostering a Healthy Organization

06 Company Information

07 Appendix: Olympus History



01

**As a Globally Leading MedTech
company**

Corporate Philosophy

OUR PURPOSE
Making people’s lives healthier, safer and more fulfilling

OUR CORE VALUES

				
PATIENT FOCUS	INTEGRITY	INNOVATION	IMPACT	EMPATHY
We put patients at the heart of everything.	We do the right thing.	We look for new ways to make things better.	We take accountability and get things done.	We care for one another and work together.

Since developing the world's first practical gastroscope in 1950, Olympus has worked alongside healthcare professionals to contribute to the evolution of endoscopy.

To embody Our Purpose of “Making people’s lives healthier, safer and more fulfilling,” we are committed to elevating the standard of care to improve outcomes.

Patient Focus, Integrity, Innovation, Impact, and Empathy: our redefined set of five core values. We continuously develop them as a global MedTech company, prioritizing patient safety and quality.




OLYMPUS

True to Life

"True to Life" is our global brand message that expresses Olympus's commitment to Our Purpose.

At Olympus, we believe everyone should have the opportunity to live life to the full. Every day we are advancing medical technology solutions to help people everywhere fulfill their desires, their curiosity, their dreams, their ambitions, and their lives.

Olympus Locations



29,297

Employees Worldwide*

40

Countries or Regions*

* As of March 2025

Our Contribution to Patients Care

49 million

Colonoscopies Performed Worldwide Annually

*Numbers of US, Germany, France, UK, Italy, Spain, Japan, Canada, Poland, South Korea, Australia, India, Russia (as of 2022); China (as of 2019 including annual averages from 2019 to 2022 forecasts)

100

Diseases or Conditions Treated

At Olympus we have versatile medical devices with the ability to treat approximately 100* diseases or conditions
Source: Based on the Company's research, as of March 2025

TOP 3

Cancers Treated

Olympus provides products/solutions for lung, colorectum and stomach - Three cancers from the top 5* highest incidence of cancers
*Top 3 highest incidence of cancers excluding breast and prostate cancer Source: GLOBOCAN 2022
<https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf>

TOP 100

Global Innovator

Since 2012 to 2020, and in 2022 and 2023, Olympus has been awarded as one of the top 100 most innovative companies in the world.
<https://clarivate.com/top-100-innovators/>

297

Awards

Since 1966, Olympus has been consistently honored with national and international design awards for its innovative product designs*
*As of March 2025

15,000

Patents


across our product portfolio*
*As of March 2025



02

Our Business Field



Revenue by Business Divisions/Region



Note: We re-aligned our divisional structure from April 2025. The Endoscopic Solutions Division (ESD) and the Therapeutic Solutions Division (TSD) transitioned into the new divisions of the Gastrointestinal Solutions Division (GIS) and the Surgical & Interventional Solutions Division (SIS).

*Due to rounding, the total may not add up to 100%

Revenue and Operating Profit



*Due to rounding, the total may not add up to 100%

Gastrointestinal Solutions Division

Gastrointestinal Endoscopy System



Video endoscopy system




Ultrasound system


GI Endotherapy



CRC devices



HPB devices



Hemostasis

Endoscopic Solutions Ecosystem (Digital Healthcare Solutions)



Intelligent ecosystem operating software platform



AI insights and computer-aided detection/diagnosis

Reprocessing



Endoscope reprocessor



Chemicals, accessories, and peripherals

Medical Services



Repair center

Note: We re-aligned our divisional structure from April 2025. The Endoscopic Solutions Division (ESD) and the Therapeutic Solutions Division (TSD) transitioned into the new divisions of the Gastrointestinal Solutions Division (GIS) and the Surgical & Interventional Solutions Division (SIS).

Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

The Digital Healthcare Solution Products and Technology shown on this slide are Concepts and Solutions Under Development – These products have not been submitted to the FDA and are Not available for Sale in the U.S.A.

Surgical and Interventional Solutions Division

Respiratory



Bronchoscopy Systems



Bronchoscopic Devices



Lung Cancer



COPD

(Chronic Obstructive Pulmonary Disease)

Urology



Visualization



Stone Management



BPH

(Benign Prostatic Hyperplasia)



BPH + Bladder Cancer

Surgical (Surgical Endoscopy, Surgical Devices, Ear, Nose, and Throat)



Surgical Endoscopy Systems



Advanced Energy Devices



Surgical Microscope



Integrated Procedure Room Solutions



Rhino-laryngoscopy Systems

Note: We re-aligned our divisional structure from April 2025. The Endoscopic Solutions Division (ESD) and the Therapeutic Solutions Division (TSD) transitioned into the new divisions of the Gastrointestinal Solutions Division (GIS) and the Surgical & Interventional Solutions Division (SIS).

Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

The Digital Healthcare Solution Products and Technology shown on this slide are Concepts and Solutions Under Development – These products have not been submitted to the FDA and are Not available for Sale in the U.S.A.



03

Company Strategy

Guiding Principles

Patient safety and sustainability



- 1 Resolve pending commitments to the FDA, build a foundation of trust through measurable actions and data with regulatory bodies and with our customers.
- 2 Lead in organization health and ESG

Innovation for growth



- 3 Strengthen the Olympus® brand; elevate the experience of our customers
- 4 Grow our business through purposeful innovation and acquisitions


Productivity



- 5 Build a high performing organization focused on patient safety and product quality
- 6 Support simplicity and operational efficiency

“ Making people’s lives healthier, safer, and more fulfilling. ”

Olympus aims to grow by focusing on three therapeutic areas



We **target three therapeutic areas** which are a strategic fit with our mission to **elevate the standard of care**, for which we can provide **differentiated value through our core capabilities**, and for which there is **growing demand**.

Activities to enable investments and innovation



QARA – functional transformation globally

- Execute transformation with the aim of a **single global quality system** and fully harmonize processes
- **Enhance Global Quality and Compliance functions** to support consistent execution
- Resolve compliance issues and **complete remediation**



R&D – investments to accelerate innovation

- Apply an **unmet need-oriented innovation** approach
- Invest for future by furthering an **innovation engine**
- Pro-actively seek out **strategic partnerships**
- **Work to accelerate time-to-market**



Mfg & SCM – opportunity for COGS improvements

- Improve **efficiency and cost** to apply a fit-for-purpose organization and processes
- Actions include **site and resource streamlining, fast-track efficiencies, procurement and supply chain** best-practices, and uncover benefits from digitization



Global TOM* – efficiencies by an improved operations

- Further fine-tune our **global governance and operation** to establish a high-performing organization of a global medical company that **unlocks capital to drive innovation**
- Enable **cross-functional and effective decision-making, with efficient resource allocation** and rigorous execution to fund & deliver key projects *TOM = target operating model

Support patient safety according to the highest industry standards

FY2026 Consolidated Forecasts

Revenue
¥ 999.0 billion
 +4 % / 0 %

Adjusted operating profit
¥ 175.0 billion
 +1 % / -7 %

Adjusted operating margin
17.5%
 -1.4 pt

■ % YoY after FX adjustment
 ■ % YoY including FX

GIS Gastrointestinal Solutions Division

FY2026 Forecasts



Revenue growth after FX adjustment **+4%**
 Adjusted operating profit **¥173.5 billion**
 Adjusted operating margin **25.6%**

SIS Surgical & Interventional Solutions Division

FY2026 Forecasts



Revenue growth after FX adjustment **+3%**
 Adjusted operating profit **¥22.0 billion**
 Adjusted operating margin **6.9%**

A background image showing a pair of hands cupped together, holding a small green seedling with three leaves growing out of a mound of dark brown soil. The entire image is overlaid with a semi-transparent blue filter. The number '04' is positioned on the left side of the image.

04

For a Sustainable Society

Common Topics in ESG*



Environment

- Climate Change / Carbon Neutrality
- Circular Economy
- GHG Emissions
- Water & waste management



Social

- Human Rights
- Inclusion
- Workplace safety
- Healthcare Access & Outcome



Governance

- Corporate Risk Management
- Management Structure
- Reporting Transparency

*Major examples only / not limited

ESG six focus areas and materiality topics for contributing to solutions to social issues



Healthcare Access and Outcome

Contribution to health equity and access



Compliance, Product Quality and Safety

Quality and safety in product, service and solution



Responsible Supply Chain

Supply chain risk mitigation and resilience




Healthy Organization

Inclusion



Carbon Neutral Society and Circular Economy

Circularity through product stewardship, carbon emissions (Scope 1, 2 and 3)



Corporate Governance

Corporate governance and reporting transparency

Focus Area 1 : Healthcare Access and Outcome



Olympus recognizes the healthcare business as a domain conducive to our efforts in contributing to society by exercising our prowess in the areas in which we most excel. We will aim to contribute to society by delivering innovative products that facilitate improved healthcare outcomes and training opportunities for HCPs.

Materiality Topics

Top Priority

- Contribution to health equity and access
 - Contribution to health equity
 - HCP training and enablement
 - Strategy to improve accessibility to product

KPI

CRC* related training in target emerging countries and regions:
+20%

CRC* related online/hybrid training provided with HCPs globally:
+20%

*CRC: Colorectal cancer

High Priority

- Innovation to improve healthcare outcomes
- Public awareness building on early detection and treatment

Others

- Corporate citizenship and philanthropy

Contribution to SDGs



Focus Area 2 : Compliance, Product Quality and Safety



As a company providing medical devices, Olympus' foremost priority should be the safety of patients. We are endeavoring to observe anti-corruption and other compliance measures and our accordance with the laws and regulations of respective countries to prioritize the quality and safety of our products.

Materiality Topics

Top Priority ■ Quality and safety in product, service, and solution

KPI

Timely ESG disclosures according to SASB* Standards

*SASB: Sustainability Accounting Standards Board

High Priority ■ Business ethics and compliance
■ Privacy, information, and cyber security

Others ■ Tax transparency
■ Ethical marketing practice
■ Risks and crisis management, and risk culture
■ Innovation to improve manufacturing process

Contribution to SDGs



Focus Area 3 : Responsible Supply Chain



Materiality Topics

Top Priority	■ Supply chain risk mitigation and resilience
KPI	Annual assessment/monitoring for multi-tier supply chain risks
High Priority	■ Human rights commitment in supply chain management

Contribution to SDGs



The stable provision of medical devices is indispensable to provide stable availability of healthcare in society. In addition to fulfilling our responsibility to deliver a stable supply of our products, we will actively work together with our suppliers to address social issues, such as those involving the environment and human rights.

Focus Area 4 : Healthy Organization



Olympus defines a healthy organizational culture as one in which each and every employee can perform at their best, and is engaged in a variety of initiatives towards its aim of becoming such an organization.

Materiality Topics

Top Priority

- Inclusion

KPI

Eligible employees in Japan* taking parental leave
by FY2026 : **100%**

*Olympus Corporation

*New KPIs & targets, which may differ based upon region, are under consideration along with changing the materiality topic from “Diversity, Equity & Inclusion” to a focus on “Inclusion”

High Priority

- Employee development and engagement
- Workplace safety and human rights

Contribution to SDGs



Focus Area 5 : Carbon Neutral Society and Circular Economy



Olympus recognizes climate change as a serious issue that endangers the integrity of the global environment, as well as being an issue which affects our business activities. We will continue to promote a variety of ongoing initiatives toward the achievement of carbon neutrality into the future.

Materiality Topics

Top Priority

- Scope 1 and 2 carbon emissions
- Scope 3 emissions
- Circularity through product stewardship

KPI

Net-zero:

Net-zero GHG emissions across Scope 1, 2, and 3 by 2040

Carbon Neutral:

In our site operations across Scope 1 and 2 by 2030

High Priority

- Water and waste management
- Climate risk resilience

Others

- Environmental reporting transparency

Contribution to SDGs



Focus Area 6 : Corporate Governance



Olympus has, over the course of many years, focused on strengthening our corporate governance so that we remain a company that is trusted by our stakeholders. We recognize that doing so is of vital importance for the sustainability of our company and will continue to strive to enhance corporate governance into the future.

Materiality Topics

Top Priority

- Corporate governance and reporting transparency

KPI

Enterprise Risk Management:
Applied consistently across the globe

Others

- Involvement of other stakeholders

Contribution to SDGs





05

Fostering a Healthy Organization

An Evolution in Corporate Culture



Healthy Organization

The Healthy Organization holds true to Olympus' ambition to create a culture that empowers employees to fulfil Our Purpose of making lives healthier, safer and more fulfilling. Living Our Core Values and acting in line with those behaviors lays the foundation for a Healthy Organization.

To develop our culture and fulfill Our Purpose we must operate in a purpose-driven way, enabled by a people-centric perspective.

Employee Engagement Survey

2021	Core Values Survey <ul style="list-style-type: none">▪ Follow-up measures: Taking action in each region to improve the issues identified from the survey
2022	Core Values Interim Survey <ul style="list-style-type: none">▪ Received FDA warning letters▪ Launched remediation and quality transformation program Elevate
2024	Our Core Values refresh <ul style="list-style-type: none">▪ Conduct initiatives to activate new core values
	 Employee Listening Program <ul style="list-style-type: none">▪ Aim to empower employees to speak up and ensures their feedback is transformed into impactful actions.

Olympus has actively implemented and tracked measures from the last Core Values Survey. Since then, company-wide initiatives have since included site visits by Executive Officers, optimization of decision-making processes, monitoring and follow-up on employee work-life balance, and the creation and implementation of standardized Global Working Guidelines.

In November 2022, we conducted an interim Core Values Survey Check-in to assess the state of our organization. Based on the results, we reinforced and adjusted various activities to improve our culture and employee experience.

Looking ahead, Olympus is developing a comprehensive, company-wide employee listening program that goes beyond traditional surveys. This program aims to empower employees to speak up and ensures their feedback is transformed into impactful actions that drive positive change and foster continuous improvement within a Healthy Organization.

Our Development and Learning Offers Support Professional Growth and Global Collaboration

	Olympus Purpose, Values, Culture	Personal and Professional Growth	Functional / Job Based Skill Building
Leaders		<ul style="list-style-type: none">▪ Leadership Programs▪ 360 Feedback for Leaders	<ul style="list-style-type: none">▪ Product and Sales Trainings
Individuals	<ul style="list-style-type: none">▪ Onboarding Sessions▪ Our Core Values Activation▪ Inclusion Training	<ul style="list-style-type: none">▪ Business Skills▪ Language Courses▪ Cross-cultural Collaboration Workshops	<ul style="list-style-type: none">▪ Trainings for Employees in Manufacturing and Repair
Teams		<ul style="list-style-type: none">▪ Career Workshops	<ul style="list-style-type: none">▪ Marketing Academy

Olympus provides a wide range of development offers, both on a global and regional/local level, directed at leaders, individual contributors, and teams.

In addition, we focus on learning with and from each other to build our professional and personal skills.

06

Company Information



Company Outline

Company Name	Olympus Corporation
Market	Tokyo Stock Exchange, Prime Market (7733)
Established	October 12, 1919
Head Office	2951 Ishikawa-machi, Hachioji-shi, Tokyo 192-8507, Japan
Share Capital	124.643 billion yen (As of March 31, 2025)
Consolidated Revenue	997.3 billion yen (Fiscal year ended March 31, 2025)
Consolidated Headcount	29,297 (As of March 31, 2025)
Corporate Website	https://www.olympus-global.com/



Key Overseas Production Sites

U.S.A.: Manufacturing sites: 2 sites

Center Valley (HQ)

Brooklyn Park

Product types: Surgical energy devices

Redmond

Product types: Bronchoscopy devices;
Spiration valve system

Westborough

(Therapeutic Equipment Business HQ)

Europe: 5 Manufacturing sites

Germany: Hamburg (HQ)

Product types : Surgical rigid speculum

Germany: Berlin

Product types : High frequency generator

Czech Republic: Přerov

Product types: Urological devices

United Kingdom: Plymouth

Product types: Medical related products

United Kingdom: Southend-on-Sea

Product types : Endoscope peripheral
equipment (trolley, insufflator)

Asia: Manufacturing sites: 2 sites

China: Beijing (HQ)

Suzhou


Endoscope assembly (planned)

Hong Kong (HQ)

Vietnam

Product types : Treatment devices

Domestic Sites and Production Sites



Executive Officers



Yasuo Takeuchi

Director, Representative Executive Officer, Executive Chairperson and ESG Officer



Bob White

Representative Executive Officer, President and Chief Executive Officer



John de Csepel

Executive Officer and Chief Medical Officer



Frank Drewalowski

Executive Officer and Gastrointestinal Solutions



Tatsuya Izumi

Executive Officer and Chief Financial Officer



Gabriela Kaynor

Executive Officer and Chief Strategy Officer



Tetsuo Kobayashi

Executive Officer and Chief Manufacturing and Supply Officer



Seiji Kuramoto

Executive Officer and Surgical and Interventional Solutions



Syed Naveed

Executive Officer and Chief Technology Officer



Shigeto Ohtsuki

Executive Officer and Chief Human Resources Officer



Boris Shkolnik

Executive Officer and Chief Quality Officer



Neil Boyden Tanner

Executive Officer and Global General Counsel



07

Appendix: Olympus History

Olympus History



Sales launch of **Asahi** microscope.

1920



Renaming of company to **Olympus Optical Co., Ltd.**

1949



Start up of **Olympus Optical Co.** in Hamburg, Germany, as Olympus' European headquarters.

1964



Collaboration with Winter & Ibe GmbH to produce surgical rigid medical endoscopes, with Olympus supplying the optical systems.

1975

1919

Founding of **Olympus** by Takeshi Yamashita under the company name **Takachiho Seisakusho**; established in Tokyo, Japan, for domestic production of microscopes.



1936

Launch of first Olympus camera, the **Semi-Olympus I**, after development of Zuiko photographic lenses.

1950

Development of world's **first practical** gastrocamera.



1968

Establishment of **Olympus Corporation of America** as a sales subsidiary for microscopes and medical equipment in the United States.



Olympus History



*Not Available for Sale in the United States

For more details, please visit [our website](#).

OLYMPUS

A thick, yellow, horizontal swoosh that tapers at both ends, positioned directly beneath the word "OLYMPUS".

Olympus is a registered trademark of Olympus Corporation, Olympus America Inc., and/or their affiliates.